ACTEMRA®

Please Fax Completed Form To: 888-898-9113

Please Send a Copy of The Patient's Insurance Cards (Front & Back)

Please Send a Copy of The Patient's Up-to-Date Clinical Notes

PATIENT INFORMATION (Complete or Fax Existing Chart)

Name: ________________________________ DOB: ____________

Address: ____

City, State, Zip: ____

Phone: ____________________ Alt. Phone: ________________

Email: __________________________ SS#: ________________

Gender: ☐ M ☐ F Weight: _______(lbs) Ht: _______________

Allergies: ____

PRESCRIBER INFORMATION

Prescriber Name: ____

State License: ____

NPI #: __________________ Tax ID: _______________________

Address: ____

City, State, Zip: ____

Phone: ______________________ Fax: ______________________

Office Contact: _______________________ Phone: ______________

INSURANCE INFORMATION – AND – Send a copy of the patient's prescription/insurance cards (front & back)

Primary Insurance: ______________________________________

Plan #: ____

Group #: ____

RX Card (PBM): ____

BIN: _________________________ PCN: ________________________

Secondary Insurance (If Applicable): ______________________

Plan #: ____

Group #: ____

RX Card (PBM): ____

BIN: _________________________ PCN: ________________________

CLINICAL INFORMATION

Primary ICD-10 Code (Please Specify Diagnosis): ____

Secondary ICD-10 Code (Please Specify Diagnosis): ____

Date of negative TB test: _____________ ☐ TB test pending, will fax results. Patient is HBV negative or has been treated: ☐ Yes ☐ No

History of kidney disease: ☐ Yes ☐ No *If yes*, SCr: _______ GFR/CrCl: ________ History of heart failure: ☐ Yes ☐ No

Required Labs/Results: ☐ ANC: ______________ ☐ Platelet: ______________ ☐ SCr: ______________ ☐ Lipids: ______________

☐ AST: ______________ Upper limit of normal: ______________ ☐ ALT: ______________ Upper limit of normal: ______________

ACTEMRA® ORDERS

Prescription type: ☐ New start ☐ Restart ☐ Continued therapy Total Doses Received: __________ Date of Last Injection/Infusion: __________

Medication	Strength	Dose/Frequency	Refills
☐ Actemra (Tocilizumab)	☐ 20mg/mL vial ☐ Other: __________	☐ 4mg/kg IV every 4 weeks with max dose of 800 mg for weight >100 kg ☐ 6mg/kg IV every 4 weeks with max dose of 600 mg for weight >100kg ☐ 8 mg/kg IV every 4 weeks with max dose of 800 mg for weight >100kg ☐ Other: ____	__________

INFUSION REACTION ORDERS

Mild reaction protocol:

☒ Diphenhydramine 25mg IV, one time, for pruritus.

If symptoms worsen, see orders for moderate to severe reactions.

Moderate reaction protocol:

☒ Acetaminophen 650mg PO, one time, for pyrexia or rigors

☒ Diphenhydramine 50mg IV, one time, for pruritus or urticaria

☒ Famotidine 20mg IV, one time, for, for pruritus or urticaria

☒ Methylprednisolone 125mg IV, one time, for respiratory or neurologic symptoms

If symptoms worsen, see interventions for severe reactions

Severe reaction protocol: (Call 911 if initiated):

☒ Titrate oxygen via continuous flow per nasal cannula or face mask to maintain spO2 of greater than ninety-five percent (>95%)

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.

TALIS HEALTHCARE
AN INFUSION MANAGEMENT COMPANY

ACTEMRA®

Please Fax Completed Form To: 888-898-9113

Please Send a Copy of The Patient's Insurance Cards (Front & Back)

Please Send a Copy of The Patient's Up-to-Date Clinical Notes

☒ Diphenhydramine 50mg IV,one time, for respiratory symptoms, edema, or anaphylaxis

☒ Methylprednisolone 125mg IV, one time, for respiratory symptoms, edema, or anaphylaxis

☒ Sodium Chloride 0.9% 500mL IV over 30-60 min, one time, for cardiovascular symptoms

☒ Epinephrine 0.3mg/0.3mL IM into mis-anterolateral aspect of thigh of anaphylaxis, may repeat x1 in 5-15 minutes if symptoms are not resolved or worsen

FLUSHING & LOCKING ORDERS

Flushing Protocol (>66lbs/33kg)

PIV and Midline:	**Implanted Port, PICC, Tunneled Catheter, and Non-tunneled Catheter:**
☒ 0.9% Sodium Chloride 2-5mL IV flush before and after each infusion	☒ 0.9% Sodium Chloride 5mL IV flush before infusion/lab draw and 10mL IV flush after infusion/lab draw

Locking Protocol (>66lbs/33kg)

PIV and Midline:	**PICC:**	**Implanted Port, Tunneled Catheter, and Non-tunneled Catheter:**
☒ Heparin Sodium 10 units/mL 1mL IV final flush post normal saline flush	☒ Heparin Sodium 10 units/mL 3mL IV final flush post normal saline flush	☒ Heparin Sodium 100 units/mL 3-5mL IV final flush post normal saline flush

**** May substitute Dextrose 5% in Water, or alternative, for 0.9& Sodium Chloride, when indicated due to incompatibility with medications bring infused**

SIGNATURE

We hereby authorize Talis Healthcare LLC to provide all supplies and additional services (nursing/patient training) required to provide and deliver the medicine as prescribed in this referral.

X____ Date: ____________________

Prescriber Signature

To ensure payment by insurance carrier, please include supporting clinical documentation for specified ICD 10 Code, demographic, and insurance information along with faxed order. Initial appointment will be verified upon insurance approval.

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.